 |
BioWorld-International-2008-07-16
Actelion, GSK Ink $3.2B Deal with Almorexant as Centerpiece
Actelion, GSK Ink $3.2B Deal with Almorexant as Centerpiece
Actelion Ltd. entered potentially it's biggest ever deal, a strategic collaboration in the area of orexin antagonists with GlaxoSmithKline plc that could be worth up to CHF3.3 billion (US$3.2 billion) in up-front, development and sales-related milestones. (BioWorld International)
Ariana Pharma Raises €1.5M for Decision-Support Tools
No Abstract
BioWorld International Correspondent
PARIS - Ariana Pharma, which is developing decision-support tools to support the drug discovery process, closed a series A funding round in which it raised €1.5 million (US$2.35 million).